Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

• Published in: The Lancet infectious diseases Vol. 22; no. 11; pp. 1596 - 1605
• Main Authors: van der Boor, Saskia C, Smit, Merel J, van Beek, Stijn W, Ramjith, Jordache, Teelen, Karina, van de Vegte-Bolmer, Marga, van Gemert, Geert-Jan, Pickkers, Peter, Wu, Yimin, Locke, Emily, Lee, Shwu-Maan, Aponte, John, King, C Richter, Birkett, Ashley J, Miura, Kazutoyo, Ayorinde, Morolayo A, Sauerwein, Robert W, ter Heine, Rob, Ockenhouse, Christian F, Bousema, Teun, Jore, Matthijs M, McCall, Matthew B B
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.11.2022; Elsevier Limited; Elsevier Science ;, The Lancet Pub. Group
• Subjects: Adult; Adverse events; Animals; Antibodies, Monoclonal - therapeutic use; Antimalarials; Aquatic insects; Clinical trials; Culicidae; Enzyme-linked immunosorbent assay; FDA approval; Fertilization; Gametocytes; Human subjects; Humans; Infections; Infectious diseases; Intravenous administration; Laboratories; Malaria; Malaria Vaccines; Malaria, Falciparum - drug therapy; Malaria, Falciparum - parasitology; Malaria, Falciparum - prevention & control; Midgut; Monoclonal antibodies; Mosquitoes; Parasites; Pharmacodynamics; Pharmacokinetics; Plasmodium falciparum; Safety; Vaccines; Vector-borne diseases; Netherlands
• ISSN: 1473-3099; 1474-4457; 1474-4457
• DOI: 10.1016/S1473-3099(22)00428-5

Malaria elimination requires interruption of the highly efficient transmission of Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that binds the gamete surface protein Pfs48/45 and inhibits fertilisation, thereby preventing further parasite development in the mosquito midgut and onward transmission. We aimed to evaluate the safety and efficacy of TB31F in malaria-naive participants. In this open-label, first-in-human, dose-escalation, phase 1 clinical trial, healthy, malaria-naive, adult participants were administered a single intravenous dose of 0·1, 1, 3, or 10 mg/kg TB31F or a subcutaneous dose of 100 mg TB31F, and monitored until day 84 after administration at a single centre in the Netherlands. The primary outcome was the frequency and magnitude of adverse events. Additionally, TB31F serum concentrations were measured by ELISA. Transmission-reducing activity (TRA) of participant sera was assessed by standard membrane feeding assays with Anopheles stephensi mosquitoes and cultured Plasmodium falciparum gametocytes. The trial is registered with Clinicaltrials.gov, NCT04238689. Between Feb 17 and Dec 10, 2020, 25 participants were enrolled and sequentially assigned to each dose (n=5 per group). No serious or severe adverse events occurred. In total, 33 grade 1 and six grade 2 related adverse events occurred in 20 (80%) of 25 participants across all groups. Serum of all participants administered 1 mg/kg, 3 mg/kg, or 10 mg/kg TB31F intravenously had more than 80% TRA for 28 days or more, 56 days or more, and 84 days or more, respectively. The TB31F serum concentration reaching 80% TRA was 2·1 μg/mL (95% CI 1·9–2·3). Extrapolating the duration of TRA from antibody kinetics suggests more than 80% TRA is maintained for 160 days (95% CI 136–193) following a single intravenous 10 mg/kg dose. TB31F is a well tolerated and highly potent monoclonal antibody capable of completely blocking transmission of P falciparum parasites from humans to mosquitoes. In areas of seasonal transmission, a single dose might cover an entire malaria season. PATH's Malaria Vaccine Initiative.